替米沙坦(Telmisartan) - 药物靶点：AT1R_在研适应症：心血管疾病，原发性高血压，高血压_专利_临床

概要

基本信息

药物类型

小分子化药

别名

4'-[(1,4'-dimethyl-2'propyl[2,6'-bi-1H-benzimidazol]-1'-yl)methyl]-[1,1'-biphenyl]-2-carboxylic acid、4'-[(1,7'-dimethyl-2'-propyl-1H,3'H-2,5'-bibenzimidazol-3'-yl)methyl]biphenyl-2-carboxylic acid、Telmisartan

+ [68]

靶点

AT1R

作用方式

拮抗剂

作用机制

AT1R拮抗剂(血管紧张素II-1型受体拮抗剂)

治疗领域

心血管疾病

在研适应症

心血管疾病原发性高血压高血压

非在研适应症

糖尿病2型糖尿病糖尿病肾病+ [6]

原研机构

Boehringer Ingelheim GmbH

在研机构

Teva Pharmaceuticals Europe BVBoehringer Ingelheim Pty Ltd.

Bayer AG

+ [9]

非在研机构-

权益机构-

最高研发阶段批准上市

首次获批日期

美国 (1998-11-10),

高血压

最高研发阶段(中国)批准上市

特殊审评优先审评 (中国)

登录后查看时间轴

结构/序列

分子式C33H30N4O2

InChIKeyRMMXLENWKUUMAY-UHFFFAOYSA-N

CAS号144701-48-4

关联

336

项与替米沙坦相关的临床试验

NCT06815497

/ Not yet recruiting临床2期IIT

Phase II Non-Randomized, Unblinded, Single-Center Trial of Telmisartan in Combination With Cytotoxic Regimens in Platinum-Resistant Ovarian Cancer Versus Historical Best Supportive Care

The primary study objective is to assess progression-free survival in patients with ovarian cancer receiving telmisartan plus selected standard of care chemotherapy regimens versus historical controls.

开始日期2025-04-14

申办/合作机构

Dartmouth-Hitchcock Medical Center

[+1]

NCT06647745

/ Recruiting临床3期

A Randomized, Double-blind, Multi-center, Active-controlled, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Combination Therapy of THP-00101, THP-00102, and THP-00103 in Subjects With T2DM and Essential Hypertension

[Primary Objective] To demonstrate the superiority of the change in mean sitting systolic blood pressure (MSSBP) and hemoglobin A1c (HbA1c)on week 12 of the combination therapy of THP-00101 (dapagliflozin 10 mg) and THP-00102 (telmisartan 80 mg) compared to THP-00101 or THP-00102 monotherapy among subjects with type 2 diabetes mellitus accompanied by essential hypertension. [Secondary Objective] To comparatively evaluate secondary efficacy and safety in the THP-00101 monotherapy group, THP-00102 monotherapy group, THP-00101 and THP-00102 combination therapy group, and THP-00101 and THP-00103 (telmisartan 40 mg) combination therapy group among subjects with type 2 diabetes mellitus accompanied by essential hypertension.

开始日期2025-04-10

申办/合作机构

THPharm

CTIS2024-513351-33-00

/ Recruiting临床2期IIT

Telmisartan for portal hypertension in patients with compensated advanced chronic liver disease: A randomized placebo-controlled, double-blind trial - TECA

开始日期2025-03-26

申办/合作机构

Medical University of Vienna

100 项与替米沙坦相关的临床结果

登录后查看更多信息

100 项与替米沙坦相关的转化医学

登录后查看更多信息

100 项与替米沙坦相关的专利（医药）

登录后查看更多信息

5,968

项与替米沙坦相关的文献（医药）

2025-07-01·WATER RESEARCH

Impact of the wastewater treatment technology and storage on micropollutant profiles during reclaimed water irrigation: A wide-scope HRMS screening in a water-soil-lettuce-leachate system

Article

作者: Gkotsis, Georgios ; Iakovides, Iakovos C ; Beretsou, Vasiliki G ; Fatta-Kassinos, Despo ; Thomaidis, Nikolaos S ; Nika, Maria-Christina ; Christou, Anastasis ; Mina, Theoni ; Michael, Costas

In recent decades, climate change and global warming have intensified water scarcity, while the growing global population demands have increased. Reclaimed water (RW) has become essential, offering a viable alternative for crop irrigation in line with circular economy principles. However, although RW reuse is crucial for addressing water shortages, the presence of micropollutants still poses a challenge. The potential for micropollutants to be taken up by crops and enter the food chain still raises significant scientific concern. This work studies RW treated by conventional activated sludge followed by sand filtration and chlorination (CAS+SFC-RW) and membrane-bioreactor-treated RW (MBR-RW) in terms of micropollutant concentrations, providing insights into the differences in micropollutant profiles between the two treatments. The results demonstrate that MBR-RW generally exhibits lower cumulative concentrations of target analytes. However, the study also indicates that the storage of RW for irrigation significantly affects the presence of micropollutants, contributing to their degradation, increase or persistence. Soil analysis revealed fewer detectable micropollutants in the topsoil (0-20 cm) compared to RW, likely attributed to attenuation processes, and more micropollutants (both with respect to concentration and number) compared to deeper soil layers. Carbamazepine, 10,11-epoxide-carbamazepine, and telmisartan were found to migrate to deeper soil levels. The analysis revealed 13 micropollutants in lettuce irrigated with CAS+SFC-RW and 8 with MBR-RW, with carbamazepine and sulfamethoxazole being the most abundant. These differences are likely driven by the physicochemical properties of the compounds and plant-specific factors. Leachates examination showed the potential for contaminants to leach through soil, posing a risk for groundwater contamination. The study showed that the presence of micropollutants in RW is not directly associated with their presence in soil or lettuce, underscoring the need for regulatory policies that address not only their presence in RW but their eventual fate within the agricultural and environmental context.

2025-06-01·JOURNAL OF HAZARDOUS MATERIALS

Bioenergetic responses mediate interactive effects of pharmaceuticals and warming on freshwater arthropod populations and ecosystem functioning

Article

作者: Stoks, Robby ; Grabicová, Kateřina ; Boukal, David S ; Van Houdt, Ria ; Dekan Carreira, Vladimíra ; Verheyen, Julie ; Duchet, Claire

Freshwater ecosystems are increasingly impacted by pharmaceutical contaminants (PhACs) and climate change-induced warming. Yet, their joint effects on freshwater taxa remain unclear. This is partly due to poorly understood mechanisms linking the effects on (sub)individual scales to higher levels of ecological organisation. We investigated the responses of two aquatic arthropods, Asellus aquaticus and Cloeon dipterum, to environmentally realistic levels of a 15-PhAC mixture (total concentration: 2.9 µg/L) and warming (+4 °C above ambient) in outdoor pond mesocosms (1000 L) across winter and summer. We measured physiological traits (bioenergetic responses based on quantification of energy consumption and energy stored in proteins, sugars and lipids, and oxidative damage based on malondialdehyde [MDA] levels), population density and ecosystem functions (leaf litter decomposition and insect emergence). In winter, PhACs reduced energy availability and increased MDA levels. In contrast, PhACs increased energy availability and decreased MDA levels in summer. The stressors reduced Asellus abundance, leading to reduced leaf litter decomposition, while Cloeon emergence in summer declined due to a PhAC-induced decline in larval abundance. Warming alone consistently decreased arthropod abundances and emergence, except for Asellus abundance in winter. The stressor effects through changes in bioenergetics were stronger than their direct effects on population abundances and ecosystem functions. Our findings highlight the vulnerability of aquatic arthropods to PhAC pollution and warming, emphasising the need for effective management strategies to mitigate the effects of emerging contaminants and climate change on freshwater biota.

2025-06-01·JOURNAL OF CONTROLLED RELEASE

Hydrophobic ion pairing enables co-loading of water-soluble drugs in polymeric micelles

Article

作者: Peña, Quim ; De Lorenzi, Federica ; Daware, Rasika ; Adams, Alina ; Buhl, Eva M ; Lammers, Twan ; Shalmani, Armin Azadkhah ; Elshafei, Asmaa Said ; Ojha, Tarun ; Kiessling, Fabian ; Sofias, Alexandros Marios ; Banala, Srinivas ; Klinkhammer, Barbara Mara ; Metselaar, Josbert M ; Moeckel, Diana ; Boor, Peter ; Storm, Gert ; Shi, Yang

Polymeric micelles are widely used for the delivery of hydrophobic drugs. However, several highly potent and ubiquitously used anticancer drugs are water-soluble, complicating their (co-)formulation in polymeric micelles without having to chemically modify them. We here explore hydrophobic ion pairing to enable the co-delivery of the water-soluble anthracycline chemotherapy drug doxorubicin and the angiotensin II receptor antagonist telmisartan (a clinically used antihypertensive drug that has shown promising (pre-) clinical outcomes in combination with anthracyclines). We show that hydrophobic ion pairing of doxorubicin and telmisartan promotes the co-encapsulation of both drugs in π electron-stabilized [PEG-b-p(HPMAm-Bz)]-based polymeric micelles. The cytotoxic activity of doxorubicin is retained, and the dual drug-loaded micelles display enhanced antitumor activity in vivo as compared to the combination of the free drugs, while also exhibiting good tolerability. Taken together, this work provides proof-of-concept for hydrophobic ion pairing as a promising formulation strategy to promote multidrug nanomedicine and drug combination therapy.

148

项与替米沙坦相关的新闻（医药）

2025-04-18

·ETPharma

131 drugs fail CDSCO quality test, another Telma sample flagged as spurious

New Delhi: During the routine quality review check in March, a total of 131 drug samples failed to meet the quality standards, while one sample of the popular hypertension brand Telma 40 has been flagged as spurious. The monthly drug quality review alert issued by the Central Drugs Standard Control Organization (CDSCO) flagged 131 drug samples as “ Not of Standard Quality ” (NSQ) and one sample as “spurious.” Making the announcement, the Union Health Ministry informed that of the total 131 NSQ samples, 70 were identified by the Central Drugs Laboratories and the remaining 61 samples were identified by the State Drugs Testing Laboratories. In addition to this, one drug sample flagged as spurious is of popular hypertension brand “Telma 40 (Telmisartan Tab I.P. 40mg),” manufactured in February 2024 and was plucked by the regulators from West Bengal. As per the Union Health Ministry, “the spurious sample was manufactured by an unauthorized manufacturer using a brand name owned by another company, and currently the matter is under investigation.” In its remark, the apex drug regulator CDSCO has said, “the product is purported to be spurious, however, the same is subject to the outcome of investigation.” Notably, last month a separate batch of the same brand picked from West Bengal was flagged as spurious. The sample was manufactured in 2022, and the reason for the drug test failure was notified as the sample “does not conform to I.P.” Telma (Telmisartan) is an angiotensin II receptor blocker that decreases high blood pressure and has been commercially marketed in India for the past two decades. The branded generic drug is marketed by Glenmark and, as per an analysis from market research firm Pharmarack, it features among the top 20 brands in the country, with a moving annual total (MAT) value of around ₹483 crore. The NSQ drug samples flagged by the central drug laboratories in March include Pantoprazole manufactured by Kolkata-based Shangrila Industries; Albendazole tablets by Mumbai-based Digital Vision; Telmisartan tablets manufactured by Guwahati-based Swiss Garnier Life Sciences; among 67 others. While the NSQ samples identified by state drug testing laboratories include Norfloxacin tablets manufactured by Revat Laboratories; Glimepiride tablets by Kerala State Drugs and Pharmaceuticals; Sucralfate by Legend Industries; among 58 others. Under Section 17-B of the Drugs and Cosmetics Act, 1940, a drug shall be deemed spurious if it is manufactured under a name belonging to another drug; an imitation of, or a substitute for, another drug; resembles another drug in a manner likely to deceive; or if it bears upon its label or container the name of another drug, among several other provisions. For NSQ samples, the drugs that fail to meet quality standards or specifications are notified as NSQ, a term defined under Section 16(1)(a) of the Drugs and Cosmetics Act, 1940. By Online Bureau ,

2025-04-11

·GlobeNewswire-Health Care

Algernon Pharmaceuticals Receives Notice of Allowance from European Patent Office for Repirinast for Kidney Disease

April 08, 2025 -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is pleased to announce that it has received a notice of allowance from the European Patent Office (EPO) for patent application 19827430.0 for its lead chronic kidney disease (CKD) program drug NP-251 (Repirinast). The invention claims the use of Repirinast, either alone or in combination with telmisartan, for the treatment or prophylaxis of renal fibrosis or kidney disease. The base claims of the patent will be valid through 2038, excluding any patent term adjustments or extensions which may provide additional protection. The Company has previously announced the allowance of this patent application in the U.S., Japan and China. The patent is currently pending in Canada. Repirinast is the Company’s lead candidate for the treatment of CKD based on data showing it reduced fibrosis by 51% with statistical significance and showed an additive benefit to telmisartan in a unilateral ureteral obstruction (UUO) mouse model. Algernon’s intellectual property strategy for its repurposed drug program includes protecting its compounds by filing patent applications including method of use, dosing, and formulations, and for new composition of matter patents based on novel salt forms. “This is our first patent issued by the EPO and marks another key milestone for the Company,” said Christopher J. Moreau, CEO of Algernon Pharmaceuticals. The Company also announces a grant of 50,000 restricted share units (each, an "RSU") and 50,000 stock options to consultants of the Company. Each RSU entitles the recipient to receive one common share of the Company or a cash payment equal to the equivalent of one common share of the Company on vesting. The stock options are exercisable at $0.09 for five years from the date of grant. Both the RSUs and stock options vest on the date of grant. The RSUs and stock options are subject to approval by regulatory authorities. Repirinast was originally developed by Mitsubishi Tanabe Pharma (“Mitsubishi”) and was sold and marketed in Japan under the brand name RometTM for the treatment of Asthma. RometTM was marketed for over 25 years in Japan. Mitsubishi discontinued manufacturing and sales of the drug in 2013. Accordingly, Algernon has retained Zhejiang Ausun Pharmaceutical in Zhejiang, China to manufacture a cGMP Repirinast supply. Mast cells are recruited to sites of cellular damage, and degranulation of mast cells leads to release of a myriad of proinflammatory chemical mediators which lead to tissue damage in a self-propagating cascade. NP-251 binds to receptors on mast cells and prevents their degranulation, which the Company believes could help prevent fibrosis in multiple organ classes including the kidneys. Algernon Pharmaceuticals is a Canadian clinical stage drug development company investigating multiple drugs for unmet global medical needs. Algernon Pharmaceuticals is also the parent company of a private subsidiary called Algernon NeuroScience, that is advancing a psychedelic program investigating a proprietary form of DMT for stroke and traumatic brain injury. The content above comes from the network. if any infringement, please contact us to modify.

上市批准专利到期

2025-04-08

·米内网

【重磅】北京药企首个1类新药来袭！剑指1200亿市场

精彩内容近日，CDE官网显示，北京福元医药申报的1类新药FY101注射液获得临床试验默示许可，用于高脂血症的治疗。米内网数据显示，近年来中国三大终端六大市场（统计范围详见本文末）心脑血管系统化药销售额均超过1200亿元。FY101注射液是一款化药1类新药，其临床申请于2025年1月获得CDE承办受理，并于近日顺利获批临床，用于高脂血症的治疗，为北京福元医药首款获批临床的1类新药。米内网数据显示，受集采影响，近年来中国三大终端六大市场心脑血管系统化药市场承压，但仍维持在1200亿元以上。从治疗亚类看，高血压用药占据“半壁江山”，心脏病治疗用药、血脂调节剂占比均超过17%。近年来中国三大终端六大市场心脑血管系统化药销售情况（单位：万元）来源：米内网格局数据库2024上半年心脑血管系统化药TOP5品牌均为外资品牌，晖致的阿托伐他汀钙片以约5%的市场份额排在首位，诺华的沙库巴曲缬沙坦钠片以约4%的市场份额排位第二，阿斯利康的瑞舒伐他汀钙片以约3%的市场份额排位第三。从销售额增速看，诺华的沙库巴曲缬沙坦钠片同比大涨37.56%。2024H1中国三大终端六大市场心脑血管系统化药TOP5品牌来源：米内网格局数据库在心脑血管系统领域，北京福元医药已拥有20余个产品的生产批文，包括奥美沙坦酯片、替米沙坦片、氯沙坦钾氢氯噻嗪片、依折麦布片、阿托伐他汀钙片、苯磺酸氯地平片等畅销品种。4月1日，福元医药发布2024年业绩报告，报告期内实现营业收入34.46亿元，归母净利润4.89亿元。公司持续加码创新研发，2024年研发费用4.17亿元，同比增加18.13%，占营收比重约12%。2024年，福元医药产品研发成果丰硕，获批19个制剂品种（14个口服+5个外用）和5个原料药品种。19个制剂品种中，依折麦布辛伐他汀片、美阿沙坦钾片、丙戊酸钠缓释片（I）、美沙拉秦肠溶片、夫西地酸乳膏、卡泊三醇软膏、丙酸氟替卡松乳膏和糠酸莫米松乳膏8个品种为国内首家（视同）过评；5个原料药分别为丙戊酸、丙戊酸钠、罗替高汀、达格列净和葡甲胺。资料来源：米内网数据库、CDE官网等注：米内网《中国三大终端六大市场药品竞争格局》，统计范围是：城市公立医院和县级公立医院、城市社区中心和乡镇卫生院、城市实体药店和网上药店，不含民营医院、私人诊所、村卫生室，不含县乡村药店；上述销售额以产品在终端的平均零售价计算。数据统计截至4月8日，如有疏漏，欢迎指正！免责声明：本文仅作医药信息传播分享，并不构成投资或决策建议。本文为原创稿件，转载文章或引用数据请注明来源和作者，否则将追究侵权责任。投稿及报料请发邮件到872470254@qq.com稿件要求详询米内微信首页菜单栏商务及内容合作可联系QQ：412539092【分享、点赞、在看】点一点不失联哦

财报申请上市

100 项与替米沙坦相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00627	替米沙坦	C09CA07	DB00966

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
心血管疾病	欧盟	Actavis Group PTC ehf	2010-09-29
心血管疾病	冰岛	Actavis Group PTC ehf	2010-09-29
心血管疾病	列支敦士登	Actavis Group PTC ehf	2010-09-29
心血管疾病	挪威	Actavis Group PTC ehf	2010-09-29
原发性高血压	欧盟	Bayer AG	1998-12-11
原发性高血压	冰岛	Bayer AG	1998-12-11
原发性高血压	列支敦士登	Bayer AG	1998-12-11
原发性高血压	挪威	Bayer AG	1998-12-11
高血压	美国	Boehringer Ingelheim GmbH	1998-11-10

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
高甘油三酯血症	临床3期	德国	Bayer AG	2007-11-01
代谢综合征	临床3期	德国	Bayer AG	2007-11-01
高胆固醇血症	临床3期	美国	Boehringer Ingelheim GmbH	2006-04-01
高胆固醇血症	临床3期	捷克	Boehringer Ingelheim GmbH	2006-04-01
高胆固醇血症	临床3期	法国	Boehringer Ingelheim GmbH	2006-04-01
高胆固醇血症	临床3期	德国	Boehringer Ingelheim GmbH	2006-04-01
高胆固醇血症	临床3期	中国香港	Boehringer Ingelheim GmbH	2006-04-01
高胆固醇血症	临床3期	荷兰	Boehringer Ingelheim GmbH	2006-04-01
高胆固醇血症	临床3期	俄罗斯	Boehringer Ingelheim GmbH	2006-04-01
高胆固醇血症	临床3期	斯洛伐克	Boehringer Ingelheim GmbH	2006-04-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04518293 (GMRx2, Pubmed \| Lancet)	临床3期	高血压	1,385	GMRx2 (telmisartan 20 mg, amlodipine 2·5 mg, and indapamide 1·25 mg)	遞窪糧築網艱蓋廠艱築(遞鹽鬱蓋繭襯選淵網選) = 壓積鑰獵築夢齋襯獵齋齋繭構願襯構構築築繭 (製獵簾衊築鬱獵積齋顧 )	积极	2024-10-01
NCT02471833 (HEART, CTgov)	临床1/2期	阿尔茨海默症	61	Telmisartan 20mg (Telmisartan 20mg)	繭簾觸簾壓積構繭選淵(襯顧願襯醖憲構積築襯) = 壓醖衊膚選繭願糧範餘網範廠醖觸製鬱壓衊夢 (獵網製膚網範選積襯遞, 1425.34) 更多	-	2024-05-23
				Telmisartan 40mg (Telmisartan 40mg)	繭簾觸簾壓積構繭選淵(襯顧願襯醖憲構積築襯) = 衊繭鏇衊壓繭衊遞積築網範廠醖觸製鬱壓衊夢 (獵網製膚網範選積襯遞, 1509.02) 更多
NCT02338232 (CTgov)	N/A	急性移植物抗宿主病	32	Telmisartan	選齋積繭窪淵艱積醖蓋 = 鹽艱醖繭襯顧窪襯築構鬱範襯觸夢艱選遞艱醖 (積簾繭襯簾築襯鬱醖夢, 淵獵蓋壓積製網願襯淵 ~ 製艱廠齋觸衊遞鏇鑰醖) 更多	-	2024-05-01
NCT04360551 (CTgov)	临床2期	新型冠状病毒感染 \| 并发症	24	Telmisartan 40mg (Telmisartan)	觸膚膚願獵鏇構積齋窪(鬱鬱願淵鹽範築構鏇壓) = 鬱製獵範遞繭積鏇鬱遞齋繭淵蓋夢餘齋衊憲觸 (範構觸壓範襯鬱鑰齋醖, 繭齋糧憲選獵簾鹽獵餘 ~ 製鹽顧淵鹽顧構醖窪簾) 更多	-	2023-08-21
				Placebo (Placebo)	觸膚膚願獵鏇構積齋窪(鬱鬱願淵鹽範築構鏇壓) = 艱醖蓋衊艱構構鹽衊鹹齋繭淵蓋夢餘齋衊憲觸 (範構觸壓範襯鬱鑰齋醖, 蓋顧簾壓積齋蓋衊製製 ~ 築膚醖壓齋餘製獵製選) 更多
NCT04736329 (TRIUMF trial, Pubmed \| Egypt Heart J)	N/A	射血分数降低的心力衰竭	107	Telmisartan	遞憲夢鬱築遞夢鑰膚願(觸鏇鬱憲淵夢獵製製繭) = 網壓蓋糧淵獵淵襯衊衊衊壓積構積餘鹹鹹遞構 (遞艱獵憲積範衊獵願網 ) 更多	积极	2023-08-08
				Enalapril	遞憲夢鬱築遞夢鑰膚願(觸鏇鬱憲淵夢獵製製繭) = 窪簾願壓壓獵憲鏇齋憲衊壓積構積餘鹹鹹遞構 (遞艱獵憲積範衊獵願網 ) 更多
ESH2023	N/A	高血压	-	Telmisartan	醖艱獵蓋觸構憲襯憲憲(淵築壓繭廠夢蓋醖獵積) = 築廠衊築壓鹹願廠襯顧鑰獵構夢構網壓簾膚鬱 (願蓋範糧簾淵鹽觸獵願 )	积极	2023-06-01
				Other ARBs	醖艱獵蓋觸構憲襯憲憲(淵築壓繭廠夢蓋醖獵積) = 艱窪鬱網鹹憲網鹽簾網鑰獵構夢構網壓簾膚鬱 (願蓋範糧簾淵鹽觸獵願 )
NCT04736329 (TRIUMF trial, ESC2023)	N/A	射血分数降低的心力衰竭	107	Telmisartan	壓餘積艱遞夢鏇壓鑰築(願製繭選獵淵獵願築積) = 鹹範鬱鹹積構窪繭遞鹽醖淵願廠範壓鹽憲糧憲 (艱鹽鹹夢淵鹽醖衊積構 ) 更多	-	2023-05-20
				Enalapril	壓餘積艱遞夢鏇壓鑰築(願製繭選獵淵獵願築積) = 願願夢遞範壓築願窪觸醖淵願廠範壓鹽憲糧憲 (艱鹽鹹夢淵鹽醖衊積構 ) 更多
NCT02593110 (TELEX, CTgov)	N/A	外周动脉疾病	114	Supervised Treadmill Exercise Therapy+Telmisartan (Telmisartan + Supervised Treadmill Exercise Therapy)	製蓋夢夢膚憲壓餘鹹壓(鏇築蓋獵膚艱窪壓衊製) = 膚積襯齋製壓夢積壓鏇鏇鹽艱鏇願遞艱網鏇襯 (顧醖淵衊膚鑰衊鑰蓋艱, 67.21) 更多	-	2023-01-11
				"No exercise" control group+Telmisartan (Telmisartan + "No Exercise" Control Group)	製蓋夢夢膚憲壓餘鹹壓(鏇築蓋獵膚艱窪壓衊製) = 願簾製顧艱膚積鏇選製鏇鹽艱鏇願遞艱網鏇襯 (顧醖淵衊膚鑰衊鑰蓋艱, 47.33) 更多
NCT02593110 (Pubmed \| JAMA)	N/A	外周动脉疾病	114	Telmisartan plus exercise	選築遞範餘憲鬱遞簾艱(網網蓋鏇淵膚鹹憲醖鬱) = 夢網遞製觸衊窪觸獵艱願製憲糧網鹽網齋憲顧 (積餘鑰願繭膚鑰鬱範窪 )	不佳	2022-10-04
				Placebo plus exercise	選築遞範餘憲鬱遞簾艱(網網蓋鏇淵膚鹹憲醖鬱) = 遞觸襯鑰觸窪膚獵憲構願製憲糧網鹽網齋憲顧 (積餘鑰願繭膚鑰鬱範窪 )
ESH2022	N/A	-	582	Telmisartan	遞範顧衊鹽糧鏇窪選鹹(艱簾淵觸簾淵廠選壓壓) = 齋顧積構願夢簾蓋齋積觸構襯艱蓋觸鬱艱範願 (夢顧鏇憲鬱衊蓋構遞繭, -0.94 ~ 0.05)	积极	2022-06-01